UCB’s strategic move to acquire Candid Therapeutics for an initial $2 billion upfront, with an additional $200 million in milestone…
Read More

UCB’s strategic move to acquire Candid Therapeutics for an initial $2 billion upfront, with an additional $200 million in milestone…
Read More